Key result
Second-generation cryoballoon ablation achieved freedom from atrial tachyarrhythmias in 81.9% of patients with drug-refractory atrial fibrillation at 12 months.
Why the study?
What is the 1-year efficacy of pulmonary vein isolation using the second-generation cryoballoon in patients with drug-refractory atrial fibrillation?
Cohort (n=393)
No
What is the 1-year efficacy of pulmonary vein isolation using the second-generation cryoballoon in patients with drug-refractory atrial fibrillation?
Second-generation cryoballoon ablation provides high rates of freedom from atrial tachyarrhythmias at 1 year, particularly in patients with paroxysmal atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Supports cryoballoon PVI in refractory AF; leaves open randomized comparisons and long-term durability.
AIM: The second-generation cryoballoon (CB-Adv) is effective in achieving pulmonary vein isolation (PVI) with encouraging results. In this study, we assessed the single-procedure outcome on a 1-year follow-up period in a large sample of patients having undergone PVI for drug-resistant atrial fibrillation (AF) using the CB-Adv. METHODS AND RESULTS: A total of 393 patients (122 female, 31%; mean age 57.7 ± 12.9 years) with drug-refractory AF undergoing PVI using the novel CB-Adv were enrolled. Follow-up was based on outpatient clinic visits including Holter electrocardiograms. Recurrence of atrial tachyarrhythmias (ATas) was defined as a symptomatic or documented episode >30 s. A total of 1572 pulmonary veins (PVs) were identified and successfully isolated with 1.2 ± 0.3 mean freezes. Mean procedure and fluoroscopy times were 87.1 ± 38.2 and 14.9 ± 6.1 min, respectively. At a mean follow-up of 12 months, freedom from ATas after a single procedure was achieved in 85.8% of patients with paroxysmal atrial fibrillation and in 61.3% of patients with persistent AF (persAF). Similar success rates were observed between bonus freeze and single freeze strategies, 82.5 and 81.8%, respectively (P = 0.9). Multivariate analysis demonstrated that persAF (P = 0.04) and relapses during blanking period (BP) (P < 0.0001) were independent predictors of ATas recurrences. CONCLUSION: Freedom from any ATa can be achieved in 81.9% of patients after a single CB-Adv procedure in a large cohort of patients. A bonus freeze does not influence the clinical outcome, and reducing the duration of the cryoapplication to 3 min offers excellent results. Persistent AF and arrhythmia recurrence during the BP are strong predictors of AF recurrence.
No takes yet. Share an insight, caveat, or question.
Irfan et al. (2015) conducted a cohort in drug-refractory atrial fibrillation (n=393). Second-generation cryoballoon (CB-Adv) ablation was evaluated on Freedom from atrial tachyarrhythmias (ATas) after a single procedure. Second-generation cryoballoon ablation achieved freedom from atrial tachyarrhythmias in 81.9% of patients with drug-refractory atrial fibrillation at 12 months.
Synapse has enriched 10 related papers. Consider them for comparative context: